SPS 2018: Implementing Human iPSC-derived Cells in Early Safety Assessment & Disease Modeling

This talk was presented at the 2018 Safety Pharmacology Society Annual Meeting in Washington DC, October 2, 2018.

Dr. T.K. Feaster discusses the predictive power of human iPSC-derived cells for in vitro toxicity testing. He highlighted toxicology, drug screening, and disease models; demonstrating increased functionality and throughput valuable for identifying liabilities early in preclinical safety programs.

Dr. Sonja Stoelzle-Feix discusses the effects of “CiPA drugs” on excitation-contraction coupling in iCell Cardiomyocytes2. She describes the evaluation of the proarrhythmic potential of 23 blinded drugs on hiPSC-CMs using iCell Cardiomyocytes2 and the Nanion CardioExcyte 96 at different sites. Ion channel data and myocyte behavior are discussed and aligned.